Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy.
Cardiovasc Ther. 2013 Oct;31(5):e55-62. doi: 10.1111/1755-5922.12026.
Vernakalant is a new antiarrhythmic agent recently approved in Europe for the rapid cardioversion of recent-onset atrial fibrillation. It works by blocking early-activating K+ atrial channels and frequency-dependent atrial Na+ channels, prolonging atrial refractory periods and rate-dependent slowing atrial conduction, without promoting ventricular arrhythmia. Preclinical and clinical trials showed good toleration of this drug. The main purpose of our review is to describe all the trials that led to the incorporation of vernakalant into the current European atrial fibrillation guidelines.
维纳卡兰是一种新型抗心律失常药物，最近在欧洲获得批准，用于快速转复新近发作的心房颤动。它通过阻断早期激活的 K+ 心房通道和频率依赖性的心房 Na+ 通道，延长心房不应期和频率依赖性的心房传导减慢，而不会促进室性心律失常。临床前和临床试验显示该药物具有良好的耐受性。我们的综述的主要目的是描述所有导致维纳卡兰纳入当前欧洲心房颤动指南的试验。
